Within a growing drug discovery company, scientists acquire (either through in house synthesis or purchase) then store, retrieve, and ship solid compound samples daily between multiple locations. The efficient management and tracking of this entire process to support drug discovery is a significant challenge. This article describes a decentralized and cost-effective inventory facility that simplifies the solid compound storage and retrieval process. Standardized storage cabinets from the market are utilized, providing a cost-effective physical infrastructure. The cabinets can be distributed across storage rooms at multiple sites and arranged into spaces with a variety of dimensions, allowing the system to be retrofitted into existing facilities and scaled up easily. We can provide storage close to work areas at each location, minimizing both unnecessary movement of staff and transportation of substances. We have applied a systematic barcoding method to the compound batch identifier that correlates with its compound location. This simplifies the compound registration process as well as the process of finding and returning compounds. Additionally, a centralized electronic platform has been employed to store, update and track solid compound information, such as properties, location and quantity. Compound shipment may be initiated from different sites, and a centralized electronic platform assists the information retrieval process, ensuring each location possesses up-to-date information. The electronic platform we present streamlines the management of compound registration, location tracking, weight updates and shipment information, facilitating seamless record sharing among all stakeholders. Every step of the process can be tracked in real time by the project team. The platform can be flexibly configured to adapt to an evolving set of storage locations, with all information and processes being audited.

21 Apr 2024·The Journal of Chemical Physics

Enhancing torsional sampling using fully adaptive simulated tempering

Article

Author: Wall, Ian D ; Bodnarchuk, Michael S ; Abdel-Maksoud, Khaled ; Essex, Jonathan W ; Suruzhon, Miroslav ; Ciancetta, Antonella

Enhanced sampling algorithms are indispensable when working with highly disconnected multimodal distributions. An important application of these is the conformational exploration of particular internal degrees of freedom of molecular systems. However, despite the existence of many commonly used enhanced sampling algorithms to explore these internal motions, they often rely on system-dependent parameters, which negatively impact efficiency and reproducibility. Here, we present fully adaptive simulated tempering (FAST), a variation of the irreversible simulated tempering algorithm, which continuously optimizes the number, parameters, and weights of intermediate distributions to achieve maximally fast traversal over a space defined by the change in a predefined thermodynamic control variable such as temperature or an alchemical smoothing parameter. This work builds on a number of previously published methods, such as sequential Monte Carlo, and introduces a novel parameter optimization procedure that can, in principle, be used in any expanded ensemble algorithms. This method is validated by being applied on a number of different molecular systems with high torsional kinetic barriers. We also consider two different soft-core potentials during the interpolation procedure and compare their performance. We conclude that FAST is a highly efficient algorithm, which improves simulation reproducibility and can be successfully used in a variety of settings with the same initial hyperparameters.

01 Jan 2024·SLAS Discovery

Key aspects of modern GPCR drug discovery

Review

Author: Campbell, Adrian ; Satchell, Rupert ; Unitt, John F ; Pearce, Martin ; Young, Barbara ; Rosethorne, Elizabeth M ; Addis, Phil ; Bali, Utsav ; Swift, Denise ; Milne, Gavin ; Harborne, Steven ; Jagger, Liz ; Baron, Frank

G-protein-coupled receptors (GPCRs) are the largest and most versatile cell surface receptor family with a broad repertoire of ligands and functions. We've learned an enormous amount about discovering drugs of this receptor class since the first GPCR was cloned and expressed in 1986, such that it's now well-recognized that GPCRs are the most successful target class for approved drugs. Here we take the reader through a GPCR drug discovery journey from target to the clinic, highlighting the key learnings, best practices, challenges, trends and insights on discovering drugs that ultimately modulate GPCR function therapeutically in patients. The future of GPCR drug discovery is inspiring, with more desirable drug mechanisms and new technologies enabling the delivery of better and more successful drugs.

News (Medical) associated with Sygnature Discovery Ltd.

08 Nov 2023

·www.fiercebiotech.com

Sygnature Discovery pumps £3.75M into data management system

An investment into Azenta Life Sciences is part of Sygnature Discovery’s goal to become a market leader in the drug discovery market for hit-finding capabilities. Sygnature Discovery, a U.K.-based preclinical contractor, is pumping 3.75 million pounds sterling ($4.6 million) into Azenta Life Sciences’ compound management storage system that will allow it to store customer libraries. Azenta’s service, along with high-throughput screening (HTS) capacity, will allow automated management and screening of compounds from various sources at one location, according to a Nov. 2 press release. With it, Sygnature will be able to store more than 2 million compounds under optimal conditions for stability, and compound samples will be tracked automatically from the storage well to the final HTS assay data point. The investment is part of Sygnature’s goal to become a market leader in the drug discovery market for hit-finding capabilities. In August, Sygnature bought Canadian CRO NuChem Sciences for an undisclosed price, giving the company integrated and standalone discovery services that span medicinal, synthetic, scale-up, process and computational chemistry as well as drug metabolism and pharmacokinetics, in vitro biology and in vivo pharmacology.

Acquisition

08 Nov 2023

·www.fiercebiotech.com

Everest Clinical acquires August Research for undisclosed price

In a move to expand its footprint in Europe, Canadian CRO Everest Clinical acquired Bulgaria-based August Research. Everest Clinical, a portfolio company of Arlington Capital Partners, picked up Bulgaria-based August Research, giving the Canadian CRO a presence in Europe. August Research has experience and infrastructure in 14 countries in Western and Eastern Europe. Through the deal, Everest will be able to provide clinical trial services (CTS) offerings and other operational capabilities to its clients, including pharma, biotech and medical device companies, in Europe, the company said in a Nov. 7 press release. Financial details of the deal weren’t disclosed. Dana Leff Niedzielska and Lukasz Niedzielski, August’s founders, as well as managing directors in the company’s European offices, will remain with the combined companies, Everest said. “The acquisition of August is highly strategic for Everest as it further expands our global service offering and establishes a beachhead in one of the largest clinical trial markets in the world,” Malcolm Little, a partner at Arlington Capital, said in the release. “With the addition of several European offices to complement Everest’s existing presence in North America and Asia, Everest further engrains itself as a truly global CRO.” Everest’s deal bucks the recent trend of Canadian CROs being the target of acquisitions versus the pursuer. In recent months, Canadian CROs Cirion Biopharma, Nucro-Technics and NuChem Sciences were snapped up in acquisition deals.

Acquisition

07 Nov 2023

·www.prnewswire.com

High Throughput Screening (HTS) Market size to grow by USD 19.9 billion from 2023 to 2028; North America to account for 40% of market growth- Technavio

NEW YORK, Nov. 7, 2023 /PRNewswire/ -- The high throughput screening (HTS) market is expected to grow by USD 19.9 billion from 2023 to 2028. In addition, the market's momentum will progress at a CAGR of 12.12% during the forecast period, according to Technavio Research. The market has been segmented by Application (Target identification and validation, Primary and secondary screening, Toxicology assessment, and Stem cell research), End-user (Pharmaceutical and biotechnology companies, Academic and research institutes, and CROs), and Geography (North America, Europe, Asia, and Rest of World (ROW)). North America is estimated to contribute 40% to the growth of the global market during the forecast period. This growth is driven by the presence of key players that are constantly supporting an increasing number of pharmaceutical and biotechnology companies in this region through a diversified HTS portfolio, including BioRad Laboratories and Thermo Fisher Scientific. This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment. Read a Free PDF Sample Report Continue Reading Technavio has announced its latest market research report titled Global High Throughput Screening (HTS) Market 2024-2028 Company Profile: Agilent Technologies Inc., Aurora Biomed Inc., Axxam Spa, Beckman Coulter Inc., Bio Rad Laboratories Inc., Biomat Srl, BMG LABTECH GmbH, Charles River Laboratories International Inc., Corning Inc., Danaher Corp., DIANA Biotechnologies s.r.o, HighRes Biosolutions, JSR Life Sciences LLC, Lonza Group Ltd., Merck KGaA, NanoTemper Technologies GmbH, PerkinElmer Inc., Sygnature Discovery Ltd., Tecan Trading AG, and Thermo Fisher Scientific Inc. Agilent Technologies Inc. - The company offers high throughput screening products such as the Agilent RapidFire 400 high throughput mass spectrometry system. To access more company profiles available with Technavio, buy the report! High Throughput Screening (HTS) Market: Segmentation Analysis The market share growth by the target identification and validation segment will be significant during the forecast period. The growth of this segment will be enhanced by the progress made in identifying and validating new drug targets based on various approaches. Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View a PDF Sample Report "Besides analyzing the current market scenario, our report examines historic data from 2017 to 2021"- Technavio High Throughput Screening (HTS) Market: Market Dynamics Rise in R and D investments Increasing prevalence of chronic diseases Patent expiration of drugs Key Driver The increasing prevalence of chronic diseases is the key factor driving market growth. HTS plays an important role in the discovery process, providing valuable information and saving time and money which is expected to help drive a market for highthroughput screening. Major Trend Increasing focus on promotional activities is the primary trend shaping market growth. Identify key trends, drivers, and challenges in the market. Download a sample to gain access to this information. Related Reports: The Life Sciences Analytics Market size is estimated to grow by USD 7,830.57 million at a CAGR of 12.02% between 2023 and 2028. The cell surface markers market size is estimated to grow by USD 14,068.95 million at a CAGR of 8.25% between 2023 and 2028. What are the key data covered in this high throughput screening (HTS) market report? CAGR of the market during the forecast period Detailed information on factors that will drive the growth of the high throughput screening (HTS) market between 2023 and 2028. Precise estimation of the high throughput screening (HTS) market size and its contribution to the market in focus on the parent market Accurate predictions about upcoming trends and changes in consumer behavior Growth of the high throughput screening (HTS) market across North America, Europe, Asia, and ROW A thorough analysis of the market's competitive landscape and detailed information about companies Comprehensive analysis of factors that will challenge the growth of high throughput screening (HTS) market companies. ToC: Executive Summary Market Landscape Market Sizing Historic Market Sizes Five Forces Analysis Market Segmentation by Application Market Segmentation by End-User Market Segmentation by Geography Customer Landscape Geographic Landscape Drivers, Challenges, & Trends Company Landscape Company Analysis Appendix About Technavio Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contacts Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio

100 Deals associated with Sygnature Discovery Ltd.

100 Translational Medicine associated with Sygnature Discovery Ltd.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 26 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

Current Projects

Drug(Targets)	Indications	Global Highest Phase

CTPS1/2 inhibitors(Sygnature Discovery) ( CTPS1 x CTPS2 )	Inflammation More	Preclinical
NAV-2729 ( ARF6 )	Inflammation More	Preclinical

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis